Alexandros
Makriyannis
George D. Behrakis Chair in pharmaceutical biotechnology, director of the Center for Drug Discovery, professor of chemistry and chemical biology
Alexandros Makriyannis in the Press
How the Internet Became the ‘Cookbook’ of the Drug Trade
“We had no idea these compounds would be used illicitly,” said Alexandros Makriyannis, a professor of medicinal chemistry at Northeastern University in Boston and director of the Center for Drug Discovery there. “It didn’t occur to us.”
Scientists map the receptor that makes weed work
“People have been using cannabis for a variety of therapeutic indications for centuries,” says Alexandros Makriyannis, director of Northeastern University’s Center for Drug Discovery, and a co-author of this new research, published in Nature. In the 1960s, scientists finally started to figure that out as well. And by the 1980s, Eli Lilly had developed a […]
How Weed Works Its Magic Just Got Easier To Understand
“We found that the CB1 receptor consists of multiple sub-pockets and channels,” Dr. Alexandros Makriyannis, director of Northeastern University’s Center for Drug Discovery and a member of the international team of researchers who mapped CB1, said in a press statement. “This complex structure will allow chemists to design diverse compounds that specifically target portions of […]
Mass High Tech
Biogen Idec and MAKScientific team up on MS drug candidates
MAKScientific, LLC, a privately held company in Boston focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that it has entered into an exclusive option and collaboration agreement with Biogen Idec (NASDAQ: BIIB) to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.
Pot-based mouth spray medicine looks for U.S. approval
A quarter-century after the U.S. Food and Drug Administration approved the first prescription drugs based on the main psychoactive ingredient in marijuana, additional medicines derived from or inspired by the cannabis plant itself could soon be making their way to pharmacy shelves, according to drug companies, small biotech firms and university scientists.
Pot-based prescription drug looks for FDA OK
A quarter-century after the U.S. Food and Drug Administration approved the first prescription drugs based on the main psychoactive ingredient in marijuana, additional medicines derived from or inspired by the cannabis plant itself could soon be making their way to pharmacy shelves, according to drug companies, small biotech firms and university scientists.
